Return to homepagePandemic Pact

Monkeypox Rapid Research Response

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:4 publications

Grant number: BB/X011607/1

Grant search

Key facts

  • Disease

    mpox

  • Start & end year

    2022
    2023

  • Known Financial Commitments (USD)

    $799,019.31

  • Funder

    UK Research and Innovation (UKRI)

  • Research Location

    United Kingdom

  • Lead Research Institution

    University of Glasgow

  • Research Priority Alignment

    N/A

  • Research Category

    14

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

  • Mpox Research Priorities

    N/A

  • Mpox Research Sub Priorities

    N/A

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

4 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Smallpox vaccination campaigns resulted in age-associated population cross-immunity against monkeypox virus.

Cardiac glycosides inhibit early and late vaccinia virus protein expression.

Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses.

Temperature elevation synergises with and enhances the type-I IFN-mediated restriction of MPXV